A randomized controlled trial of early dietary supply of long‐chain polyunsaturated fatty acids and mental development in term infants

This study investigated the impact of specific long-chain polyunsaturated fatty acids (LCPUFAs) on the mental development of healthy term infants. The researchers compared three different infant formula diets:

1. **DHA-supplemented formula:** Contained 0.35% docosahexaenoic acid (DHA).

2. **DHA+AA-supplemented formula:** Contained 0.36% DHA and 0.72% arachidonic acid (AA).

3. **Control formula:** Contained no added DHA or AA.

The primary outcome measured was mental development at 18 months of age, assessed using a standardized developmental test. Secondary outcomes included psychomotor development and behavior.

The study included 56 healthy term children (26 male, 30 female) who were enrolled in the trial within the first 5 days of their life. These infants were fed their assigned diet from enrollment until they reached 17 weeks of age. All assessments, including the final mental development evaluation, were conducted at the Retina Foundation of the Southwest in Dallas, TX. The focus was specifically on healthy infants born at term (not premature), which means the findings may not directly apply to infants with other health conditions or those born prematurely.

The primary measure of mental development at 18 months of age was the **Bayley Scales of Infant Development, 2nd edition (BSID-II)**. This is a widely recognized and standardized assessment tool used to evaluate developmental functioning in infants and young children, typically from 1 to 42 months of age. The BSID-II provides scores across several key areas:

**Mental Development Index (MDI):** This is a composite score that reflects cognitive and language abilities. It includes subscales for cognitive and language development. A higher MDI score indicates more advanced mental development.

**Psychomotor Development Index (PDI):** This score assesses gross and fine motor skills.

**Behavior Rating Scale:** This scale evaluates the child's behavior during the assessment, providing insights into their attention, persistence, and emotional regulation.

The study specifically reported findings for the MDI, its cognitive and motor subscales, the language subscale, the PDI, and the Behavior Rating Scale.

Additionally, these children had undergone earlier assessments at 4 months and 12 months of age, which included:

**Blood fatty-acid composition:** This measured the levels of specific fatty acids, like DHA, in their plasma and red blood cells, to confirm that the dietary supplementation was effectively increasing their body's levels of these nutrients.

**Sweep visual evoked potential (VEP) acuity:** A measure of visual function that assesses how well the brain processes visual information.

**Forced-choice preferential looking (FPL) acuity:** Another measure of visual acuity, based on an infant's natural tendency to look at more complex or novel patterns.

While these earlier visual assessments and blood analyses were conducted, the abstract for *this specific report* focuses primarily on the 18-month mental development outcomes.

This study was designed as a **randomized controlled trial (RCT)**. This is considered the gold standard for clinical research because it allows researchers to establish a cause-and-effect relationship between an intervention (the supplemented formula) and an outcome (mental development).

Here's a breakdown of the methodology and its implications:

**Randomization:** Infants were "randomized" into one of the three diet groups (DHA-supplemented, DHA+AA-supplemented, or control). Randomization means that each infant had an equal chance of being assigned to any of the groups. The purpose of randomization is to ensure that, on average, the groups are similar in all characteristics at the start of the study, except for the intervention they receive. This helps to minimize bias from confounding factors (e.g., differences in parental education, socioeconomic status, or genetics) that could otherwise influence the results. If the groups are balanced, any observed differences in outcomes can be more confidently attributed to the dietary intervention.

**Control Group:** The inclusion of a "control formula" group (without DHA or AA) is crucial. This group serves as a baseline for comparison, allowing researchers to determine if the supplemented formulas actually *improve* development beyond what would naturally occur without the intervention. Without a control group, it would be impossible to know if any observed development was due to the formula or simply normal growth.

**Blinding:** The abstract does not explicitly state whether the study was blinded. In nutritional intervention studies, especially with infant formulas, it can be challenging to blind parents and caregivers to the specific formula their child is receiving, as different formulas might have subtle differences in appearance, smell, or even how they are packaged. However, it is often possible to blind the researchers who are performing the assessments (e.g., the psychologists administering the BSID-II) to the child's diet group. If the assessors were not blinded, there is a potential for observer bias, where their knowledge of the child's group could unconsciously influence their scoring. The absence of explicit mention of blinding for assessors is a potential methodological weakness, though it's common for abstracts to omit such details if space is limited.

**Duration of Intervention:** Infants were enrolled within the first 5 days of life and fed their assigned diet until 17 weeks of age (approximately 4 months). This early and relatively short duration of intervention is significant because it suggests that the benefits observed at 18 months stemmed from nutritional input during a critical period of early brain development. The fact that the intervention stopped at 17 weeks but effects were seen at 18 months indicates a lasting impact.

**Follow-up Duration:** The primary outcome was assessed at 18 months of age, which is well after the intervention period ended. This extended follow-up allows for the evaluation of longer-term effects of early nutrition.

**Statistical Approach:** The abstract mentions "significant developmental age advantage" and "did not reach statistical significance." This indicates that statistical tests were performed to compare the groups and determine the probability that the observed differences occurred by chance. A result is typically considered "statistically significant" if the probability of it occurring by chance (the p-value) is below a predetermined threshold, often 0.05. The abstract, however, does not provide specific p-values or confidence intervals, which limits the ability to fully interpret the strength and precision of the findings.

**What this design can and cannot prove:**

* **Can prove:** As an RCT, this study can provide strong evidence for a causal link between early dietary supplementation with DHA and AA and improved mental development in healthy term infants. The randomization helps ensure that the groups were comparable at baseline, and the control group provides a clear comparison.

* **Cannot prove:**

* **Generalizability:** The findings are specific to healthy term infants fed formula. They may not directly apply to breastfed infants, premature infants, or infants with underlying health conditions.

* **Long-term effects:** While the follow-up was to 18 months, it doesn't tell us about cognitive development in childhood, adolescence, or adulthood. The benefits might persist, diminish, or even change over time.

* **Optimal dose/duration:** The study tested specific concentrations and a specific duration (up to 17 weeks). It does not determine if different doses, ratios of DHA to AA, or longer/shorter intervention periods would yield different or even better results.

* **Mechanism:** While it shows an effect, the study doesn't fully elucidate the biological mechanisms by which DHA and AA improve mental development, beyond suggesting that early dietary supply is a major determinant.

**Major methodological weaknesses:** The primary weakness, based solely on the abstract, is the lack of explicit mention of blinding for the outcome assessors. If the assessors were aware of which formula the infants received, there's a risk of unconscious bias influencing the BSID-II scores. Additionally, the relatively small sample size (56 children completed the 18-month assessment) means that the study might not have had enough statistical power to detect smaller but still meaningful effects, especially for secondary outcomes or specific subscales. The absence of specific statistical values (p-values, confidence intervals) in the abstract also makes a full critical appraisal challenging.

The study reported several key findings regarding the mental development of infants at 18 months of age:

**Mental Development Index (MDI) Improvement:** Infants who received formula supplemented with **DHA and AA** showed a mean increase of **7 points** on the Mental Development Index (MDI) of the BSID-II compared to the control group.

**Cognitive and Motor Subscales:** Both the cognitive and motor subscales, which contribute to the MDI, demonstrated a "significant developmental age advantage" for both the **DHA